Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 64.7%
Negative

Negative
Seeking Alpha
14 days ago
XOMA Royalty PFD Update: Going Back To My Original Sell Ratings
XOMA Royalty Corporation preferred stocks offer diversification beyond mREITs and banks, but both XOMAO and XOMAP are now rated Sell. Recent high-cost financing and low tangible common equity raise risk concerns; both preferreds trade above par with limited call risk but high downside if called. XOMAP likely faces a call first, but both issues suffer from illiquidity, negative cash flow, and asset coverage concerns relative to similar-yielding regional bank preferreds.
XOMA Royalty PFD Update: Going Back To My Original Sell Ratings
Neutral
GlobeNewsWire
14 days ago
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V.
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
Neutral
PRNewsWire
23 days ago
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October 3, 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
Neutral
GlobeNewsWire
25 days ago
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock:   Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Positive
Zacks Investment Research
28 days ago
Does XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 85.3% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect?
Neutral
GlobeNewsWire
1 month ago
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
EMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of HilleVax, Inc. (NASDAQ: HLVX) (“HilleVax”) common stock for a price per share of $1.95 in cash (the “Cash Amount”), plus one non-tradeable contingent value right (“CVR” and together with the Cash Amount, the “Offer Price”).
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know
The mean of analysts' price targets for XOMA Royalty (XOMA) points to an 86.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know
Neutral
GlobeNewsWire
1 month ago
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference.
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
Positive
Zacks Investment Research
1 month ago
Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for XOMA Royalty (XOMA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now
Neutral
GlobeNewsWire
1 month ago
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator (“XOMA Royalty”), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty (“Sub”), has agreed to acquire the entire issued and to be issued share capital of Mural for cash (the “Acquisition”) subject to the satisfaction of the closing conditions set out in Appendix I of this Announcement (the “Conditions”), including approval by Mural Shareholders. Following a strategic review process, the Mural board of directors (the “Mural Board”) determined the acquisition and cash offer by XOMA Royalty is in the best interests of all Mural Shareholders and has approved the Acquisition. The Acquisition has also been approved by the boards of directors of XOMA Royalty and Sub.
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share